Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Li Zhuang
Institutions:
The University of Texas MD Anderson Cancer Center,
Kunming Medical University,
Peking University Cancer Hospital
Observed institutions:
The University of Texas MD Anderson Cancer Center,
Kunming Medical University,
Peking University Cancer Hospital,
Fuzhou University
ORCID:
0009-0007-7441-3587
Observed ORCID:
0009-0007-7441-3587
OpenAlex ID:
A5103940303
Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer
2018
·
Pranavi Koppula
, Yilei Zhang
, et al.
·
癌症:英文版
·
920
PDF
NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation
2020
·
Xiaoguang Liu
, Yilei Zhang
, et al.
·
Genes & Diseases
·
181
PDF
BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21
2016
·
Hyemin Lee
, Fangyan Dai
, et al.
·
Oncotarget
·
62
PDF
Author Correction: DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer
2021
·
Chao Mao
, Xiaoguang Liu
, et al.
·
Nature
·
34
Metabolic underpinnings of cuproptosis
2026
·
Dadi Jiang
, Li Zhuang
, et al.
·
Cell chemical biology
·
5
Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance
2026
·
Kunzhong Zhou
, Yuewen Li
, et al.
·
Frontiers in Oncology
·
1
PDF
Development of a nomogram for predicting cancer pain in lung cancer patients: An observational study
2024
·
Yuewen Li
, Zhiyong Wang
, et al.
·
Medicine
·
1
Case Report: Application of the 6D BTS digital assessment system in the comprehensive management of refractory cancer pain in a patient with gallbladder carcinoma
2026
·
Jing Ren
, Yuewen Li
, et al.
·
Frontiers in Pain Research
PDF
Ribosome stress meets disulfidptosis: HOIL-1 safeguards cell fate during nutrient deprivation
2026
·
Yuelong Yan
, Li Zhuang
, et al.
·
Cell Death and Differentiation
PDF
Abstract CT247: Savolitinib combined with Durvalumab in EGFR wild-type advanced NSCLC patients with MET alterations (SOUND): A multicenter, open-label, Phase II trial
2026
·
Yong-Feng Yu
, Xiao-Ying Huang
, et al.
·
Cancer Research
Show more works
View as search
Works count:
10
Citation count:
1,201
H-index:
5
I10-index:
4
Year
Topic
Type